Intra-Cellular Therapies Profit Margin

Intra-Cellular Therapies (ITCI) currently reports a profit margin of -10.97% as of December 2024. That compares with -30.22% in the prior-year period — up 63.7% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Intra-Cellular Therapies's profit margin history and peer comparisons.

Intra-Cellular Therapies's profit margin increased from -30.22% to -10.97% — a 63.7% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intra-Cellular Therapies's profit margin of -10.97% is lower than the Healthcare sector average of 15.58%. That is roughly 170.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Intra-Cellular Therapies's current -10.97% should be judged against Healthcare norms (sector average: 15.58%) and against ITCI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -10.97%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Intra-Cellular Therapies, and consider following ITCI for alerts when major investors trade the stock.